Company intelligence / Profile preview

UltraShape

San Diego, California, United Statesaspmedica.com ↗

Ownership: Private
Development stage: Commercial

Overview

UltraShape developed a non-invasive body contouring device using focused pulsed ultrasound technology for permanent destruction of subcutaneous fat cells. The system was FDA-approved in 2014 for abdominal circumference reduction and further cleared as "UltraShape Power" in 2016. Clinical studies demonstrated an average loss of 1.3–2.5 inches in abdominal circumference with high patient satisfaction and minimal side effects. Over 13 clinical studies with more than 900 patients confirmed safety and efficacy.

Therapeutic areas: Metabolic DisordersOther
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on UltraShape.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UltraShape.

Explore the full profile